Amedisys (AMED) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amedisys (AMED) PT Lifted to $28 at Piper Jaffray; 'Hold' Maintained
March 5, 2015 7:20 AM ESTPiper Jaffray analyst Kevin Ellich bumped his price target on Amedisys (NASDAQ: AMED) to $28.00 (from $24.00) following in-line Q4 results but maintained a Neutral rating.
Ellich commented, "4Q14 results were in line with consensus driven by continued operational improvement. While AMED did not provide 2015 guidance,... More
